Format

Send to

Choose Destination
Curr Opin Pharmacol. 2014 Feb;14:23-9. doi: 10.1016/j.coph.2013.10.004. Epub 2013 Nov 16.

Use of predictive models in CNS diseases.

Author information

1
PharmacoMetrica, Lieu-dit Longcol, La Fouillade, France. Electronic address: roberto.gomeni@pharmacometrica.com.

Abstract

Today the CNS drug development poses serious challenges for developers given the low probability of success and the disproportionately high investment costs. This review demonstrates how predictive models can provide quantitative criteria for increasing the efficiency of drug development in CNS. Predictive models can be applied to characterize, understand, and predict a drug's PK and PD behavior; to quantify uncertainty of information about that behavior; to identify factors that could affect the outcomes of a clinical trial through Clinical Trial Simulation (CTS), to identify prognostic factors that could affect the disease progression, to implement optimal and adaptive clinical trial and finally to control the level of placebo response by implementing study designs that minimizes the impact of placebo on study outcomes.

PMID:
24565008
DOI:
10.1016/j.coph.2013.10.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center